eCFR :: 21 CFR 312,32 — IND safety reporting,

View Title 21 on govinfo,gov; View Title 21 Section 312,32 PDF; These links go to the official, published CFR, which is updated annually, As a result, it may not include the most recent changes applied to the CFR, You can learn more about the process here,

CFR

For the most up-to-date version of CFR Title 21, go to the Electronic Code of Federal Regulations eCFR, Sec, 312,32 IND safety reporting, a Definitions, The following definitions of terms apply to this section: Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug

21 CFR § 312,32 IND safety reporting

312,32 IND safety reporting, § 312,32 IND safety reporting, a Definitions, The following definitions of terms apply to this section: Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related,, Life-threatening adverse event or life-threatening suspected adverse reaction, An adverse event or suspected adverse

CFR

For the most up-to-date version of CFR Title 21, go to the Electronic Code of Federal Regulations eCFR, New Search: Help , More About 21CFR : TITLE 21–FOOD AND DRUGS CHAPTER I–FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER D – DRUGS FOR HUMAN USE : PART 312: INVESTIGATIONAL NEW DRUG …

eCFR :: 21 CFR Part 312 — Investigational New Drug

An investigational new drug offered for import into the United States complies with the requirements of this part if it is subject to an IND that is in effect for it under § 312,40 and: 1 The consignee in the United States is the sponsor of the IND; 2 the consignee is a qualified investigator named in the IND; or,

Guidance for Industry and Investigators

Fichier PDF

DEFINITIONS 21 CFR 312,32a requirements under 21 CFR part 312 and adding safety reporting requirements for persons conducting BA and BE studies under 21 CFR part 320, 1 This guidance has

21 CFR §312 Investigational New Drug Application

69 lignesTitle 21 Part 312 of the Electronic Code of Federal Regulations, Title 21, part 312 of the …

21:5,0,1,1,3,1SUBPART ASUBPART A – GENERAL PROVISIONS

21:5,0,1,1,3,1,1,1	SECTION 312,1	312,1 Scope,
21:5,0,1,1,3,1,1,2	SECTION 312,2	312,2 Applicability,
21:5,0,1,1,3,1,1,3	SECTION 312,3	312,3 Definitions and interpretations,
21:5,0,1,1,3,1,1,4	SECTION 312,6	312,6 Labeling of an investigational new

Voir les 69 lignes sur ecfr,io

21 CFR Part 312

21 CFR Part 312 – INVESTIGATIONAL NEW DRUG APPLICATION , CFR ; State Regulations prev , next, Subpart A – General Provisions §§ 312,1 – 312,10 Subpart B – Investigational New Drug Application IND §§ 312,20 – 312,38 Subpart C – Administrative Actions §§ 312,40 – 312,48 Subpart D – Responsibilities of Sponsors and Investigators §§ 312,50 – 312,70 Subpart E – Drugs Intended to

Safety Reporting Requirements for INDs Investigational

You can submit online or written comments on any guidance at any time see 21 CFR 10,115g5 If unable to submit comments online, please mail written comments to:

21 CFR Subpart B

21 CFR Subpart B – Investigational New Drug Application IND CFR ; prev , next § 312,20 Requirement for an IND, § 312,21 Phases of an investigation, § 312,22 General principles of the IND submission, § 312,23 IND content and format, § 312,30 Protocol amendments, § 312,31 Information amendments, § 312,32 IND safety reporting, § 312,33 Annual reports, § 312,38 Withdrawal of an IND, CFR

SUBPART

cite as: 21 cfr 312,21 § 312,22 – General principles of the IND submission, a FDA’s primary objectives in reviewing an IND are, in all phases of the investigation, to assure the safety and rights of subjects, and, in Phase 2 and 3, to help assure that the quality of the scientific evaluation of drugs is adequate to permit an evaluation of the drug’s effectiveness and safety,

Pt, 312 21 CFR Ch, I 4–1–12 Edition

Fichier PDF

Pt, 312 21 CFR Ch, I 4–1–12 Edition c Clinical investigations designed to obtain evidence that any drug prod-uct containing colloidal silver or silver salts labeled, represented, or promoted for any OTC drug use is safe and effec-tive for the purpose intended must comply with the requirements and pro-cedures governing the use of investiga-tional new drugs as set forth in part 312 of

Update: 21 CFR PART 312 FDA Safety Reporting Requirements

Fichier PDF

– Amended IND safety reporting requirements under 21 CFR Part 312 • Goals: – improve the overall quality of safety reporting – strengthen FDA’s ability to review critical safety information – improve safety monitoring of human drug and biological products, and harmonize safety reporting internationally • Effective date: March 28, 2011 • IND Safety Reports 312,32 • Investig

21 CFR § 312,53 Selecting investigators and monitors

312,53 Selecting investigators and monitors, § 312,53 Selecting investigators and monitors, a Selecting investigators, A sponsor shall select only investigators qualified by training and experience as appropriate experts to investigate the drug, b Control of drug, A sponsor shall ship investigational new drugs only to …